Processing

Please wait...

Settings

Settings

Goto Application

4. WO2013062444 - PEPTIDE AZEMIOPSIN SELECTIVELY INTERACTING WITH NICOTINIC ACETYLCHOLINE RECEPTORS OF MUSCLE TYPE

Publication Number WO/2013/062444
Publication Date 02.05.2013
International Application No. PCT/RU2012/000870
International Filing Date 25.10.2012
IPC
C07K 14/46 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
A61K 38/17 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
A61P 25/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
CPC
A61K 38/1787
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
177Receptors; Cell surface antigens; Cell surface determinants
1787for neuromediators, e.g. serotonin receptor, dopamine receptor
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
C07K 14/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
C07K 14/70571
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
70571for neuromediators, e.g. serotonin receptor, dopamine receptor
Applicants
  • LIMITED LIABILITY COMPANY "SYNEURO" [RU]/[RU] (AllExceptUS)
  • ZHMAK, Maksim Nurgayanovich [RU]/[RU] (US)
Inventors
  • ZHMAK, Maksim Nurgayanovich
  • UTKIN, Yury Nikolaevich
  • ANDREEVA, Tatyana Viktorovna
  • WEISE, Christoph
  • KRYUKOVA, Elena Viktorovna
  • TSETLIN, Viktor Ionovich
  • KASHEVEROV, Igor Evgen'evich
  • STARKOV, Vladislav Gennad'evich
Agents
  • ZHMAK, Maksim Nurgayanovich [RU]/[RU]
Priority Data
201114306526.10.2011RU
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PEPTIDE AZEMIOPSIN SELECTIVELY INTERACTING WITH NICOTINIC ACETYLCHOLINE RECEPTORS OF MUSCLE TYPE
(FR) AZÉMIOPSINE PEPTIDIQUE INTERAGISSANT SÉLECTIVEMENT AVEC DES RÉCEPTEURS NICOTINIQUES DE L'ACÉTYLCHOLINE DE TYPE MUSCULAIRE
Abstract
(EN)
The invention relates to the biologically active peptides which block nicotinic acetylcholine receptors and can find application in the field of biochemistry, biotechnology and medicine. Peptide azemiopsin has the following amino acid sequence:H2N-Asp1-Asn2-Trp3-Trp4-Pro5-Lys6-Pгo7-Pro8-His9-Gln10-Gly11-Pro12-Arg13-Pro14-Pro15-Arg16-Pro17-Arg18-Pro19-Lys20-Pro21-COX, where X is OH or NH2 group, and possesses the capacity to interact selectively with muscle-type nicotinic acetylcholine receptors. Peptide can be used as a basis for the development of myorelaxants selectively blocking muscle-type nicotinic acetylcholine receptors. The invention represents a new type of natural toxins interacting with nicotinic acetylcholine receptors and lacking disulphide bonds. 5 figures.
(FR)
La présente invention porte sur des peptides biologiquement actifs bloquant les récepteurs nicotiniques de l'acétylcholine et pouvant avoir des applications dans les domaines de la biochimie, des biotechnologies et de la médecine. L'azémiopsine peptidique présente la séquence d'acides aminés suivante :H2N-Asp1-Asn2-Trp3-Trp4-Pro5-Lys6-Pгo7-Pro8-His9-Gln10-Gly11-Pro12-Arg13-Pro14-Pro15-Arg16-Pro17-Arg18-Pro19-Lys20-Pro21-COX, dans laquelle X représente le groupe OH ou NH2, et possède la capacité d'interagir sélectivement avec les récepteurs nicotiniques de type musculaire de l'acétylcholine. Le peptide peut être utilisé comme base pour le développement de myorelaxants bloquant sélectivement les récepteurs nicotiniques de type musculaire de l'acétylcholine. L'invention représente un nouveau type de toxines naturelles interagissant avec les récepteurs nicotiniques de l'acétylcholine et dépourvues de ponts disulfures.
Latest bibliographic data on file with the International Bureau